Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07441486CT.gov A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07235618CT.gov A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07330544CT.gov A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy | — | Recruiting | — | — | — |
NCT07492394CT.gov Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | — | Recruiting | — | — | — |
NCT04296942CT.gov BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | — | Terminated | — | — | — |
NCT03473639CT.gov A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy | — | Completed | — | — | — |
NCT03361800CT.gov Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC | — | Terminated | — | — | — |
NCT03538171CT.gov Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT03291886CT.gov Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer | — | Completed | — | — | — |
NCT02833155CT.gov Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
Show 11 more trialsShow fewer
NCT02820961CT.gov Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | — | Completed | — | — | — |
NCT02708680CT.gov Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | — | Completed | — | — | — |
NCT02453620CT.gov Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02115594CT.gov Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer | — | Withdrawn | — | — | — |
NCT02115282CT.gov Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | — | Active Not Recruiting | — | — | — |
NCT01594398CT.gov Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01434303CT.gov Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only | — | Completed | — | — | — |
NCT01349959CT.gov Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT01234532CT.gov Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery | — | Terminated | — | — | — |
NCT00676663CT.gov Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00754312CT.gov A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Entinostat (this asset) | Tianjin Medical University Cancer Institute and Hospital | P3 | B · 56 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Entinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Triple-Negative Breast Carcinoma | — | P2 | B · 63 |
| Myelodysplastic Syndrome | — | P2 | B · 62 |
| Breast Carcinoma | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Entinostat in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/entinostat-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →